Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1 randomized, double-blind, placebo-controlled study first-in-human trial of ANX105

Next Previous
Search
Trial Profile

A phase 1 randomized, double-blind, placebo-controlled study first-in-human trial of ANX105

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANX 105 (Primary)
  • Indications Neurodegenerative disorders
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics

    • Most Recent Events

    • 08 Aug 2022 According to an Annexon media release, dosing has been initiated and trial is actively enrolling healthy participants in the SAD portion of the trial.
    • 09 May 2022 Status changed from planning to recruiting, according to an Annexon media release.
    • 09 May 2022 According to an Annexon media release, this study was initiated in the second quarter of 2022, following clearance of the clinical trial application (CTA) by Dutch regulatory authorities, with data expected in 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top